Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
The First Hospital of Jilin University
National Cancer Center, Japan
Royal Marsden NHS Foundation Trust
Coherent Biopharma (Hefei) Co., Ltd.
Centre Leon Berard
National Taiwan University Hospital
Pliant Therapeutics, Inc.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nanjing Chia-tai Tianqing Pharmaceutical
Region Stockholm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The First Hospital of Jilin University
IRCCS SYNLAB SDN
Institut Paoli-Calmettes
Institut Cancerologie de l'Ouest
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
N.N. Petrov National Medical Research Center of Oncology
University of Strathclyde
Peter MacCallum Cancer Centre, Australia
The First Affiliated Hospital with Nanjing Medical University
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
Gazi University
Centre Hospitalier Universitaire Vaudois
Fudan University
Fudan University
University of Illinois at Urbana-Champaign
Cairo University
Eunseong Medical Foundation Good GANG-AN HOSPITAL
Marmara University
Universitat Jaume I
Georgetown University
RemeGen Co., Ltd.
Ciusss de L'Est de l'Île de Montréal
Universitair Ziekenhuis Brussel
Thomas Jefferson University
Kaiser Permanente
Centre Georges Francois Leclerc
Centre Leon Berard
Sunnybrook Health Sciences Centre
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
King's College London
Allina Health System
MuÅŸ Alparslan University
National Cancer Centre, Singapore
Regina Elena Cancer Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ataturk University
Icahn School of Medicine at Mount Sinai